Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebinger, Joseph E., Fert-Bober, Justyna, Printsev, Ignat, Wu, Min, Sun, Nancy, Prostko, John C., Frias, Edwin C., Stewart, James L., Van Eyk, Jennifer E., Braun, Jonathan G., Cheng, Susan, Sobhani, Kimia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205849/
https://www.ncbi.nlm.nih.gov/pubmed/33795870
http://dx.doi.org/10.1038/s41591-021-01325-6
_version_ 1783708545292697600
author Ebinger, Joseph E.
Fert-Bober, Justyna
Printsev, Ignat
Wu, Min
Sun, Nancy
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Van Eyk, Jennifer E.
Braun, Jonathan G.
Cheng, Susan
Sobhani, Kimia
author_facet Ebinger, Joseph E.
Fert-Bober, Justyna
Printsev, Ignat
Wu, Min
Sun, Nancy
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Van Eyk, Jennifer E.
Braun, Jonathan G.
Cheng, Susan
Sobhani, Kimia
author_sort Ebinger, Joseph E.
collection PubMed
description In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
format Online
Article
Text
id pubmed-8205849
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-82058492021-07-01 Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Ebinger, Joseph E. Fert-Bober, Justyna Printsev, Ignat Wu, Min Sun, Nancy Prostko, John C. Frias, Edwin C. Stewart, James L. Van Eyk, Jennifer E. Braun, Jonathan G. Cheng, Susan Sobhani, Kimia Nat Med Brief Communication In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose. Nature Publishing Group US 2021-04-01 2021 /pmc/articles/PMC8205849/ /pubmed/33795870 http://dx.doi.org/10.1038/s41591-021-01325-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Ebinger, Joseph E.
Fert-Bober, Justyna
Printsev, Ignat
Wu, Min
Sun, Nancy
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Van Eyk, Jennifer E.
Braun, Jonathan G.
Cheng, Susan
Sobhani, Kimia
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title_full Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title_fullStr Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title_full_unstemmed Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title_short Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
title_sort antibody responses to the bnt162b2 mrna vaccine in individuals previously infected with sars-cov-2
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205849/
https://www.ncbi.nlm.nih.gov/pubmed/33795870
http://dx.doi.org/10.1038/s41591-021-01325-6
work_keys_str_mv AT ebingerjosephe antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT fertboberjustyna antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT printsevignat antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT wumin antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT sunnancy antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT prostkojohnc antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT friasedwinc antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT stewartjamesl antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT vaneykjennifere antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT braunjonathang antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT chengsusan antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2
AT sobhanikimia antibodyresponsestothebnt162b2mrnavaccineinindividualspreviouslyinfectedwithsarscov2

Ejemplares similares